体腔热灌注化疗与贝伐珠单抗联合对子宫内膜癌患者疗效评价  

Evaluation of efficacy of bevacizumab combined with coelom hyperthermia perfusion on serum malignant biological indexes in patients withendometrial carcinoma(EC)

作　　者：贾赛儒 王伟 刘美溪 刘旭 李珊珊 李玲[5] JIA Sairu;WANG Wei;LIU Meixi;LIU Xu;LI Shanshan;LI Ling(Department of Oncology,Daxing District People′s Hospital,Beijing 102600,China;Department of Emergency,Daxing District People′s Hospital,Beijing 102600,China;The Department of Internal Medicine-Cardiovascular;Department of Obstetrics and Gynecology,the Sixth Medical Center of the Chinese People′s Liberation Army General Hospital,Beijing 100048,China;Department of Traditional Chinese Medicine,Eighth Medical Center,PLA General Hospital,Beijing 100091,China)

机构地区：[1]大兴区人民医院肿瘤科,北京102600 [2]大兴区人民医院急诊科,北京102600 [3]大兴区人民医院心内科,北京102600 [4]中国人民解放军总医院第六医学中心妇产科,北京100048 [5]解放军总医院第八医学中心中医科,北京100091

出　　处：《新疆医科大学学报》2024年第8期1129-1134,共6页Journal of Xinjiang Medical University

基　　金：北京市科技计划项目(KJ2022CX78)。

摘　　要：目的探讨体腔热灌注化疗联合贝伐珠单抗在子宫内膜癌中的应用效果。方法选取2018年1月至2020年1月期间大兴区人民医院与解放军总医院第八医学中心收治的子宫内膜癌(EC)患者89例,随机分为对照组(44例)和研究组(45例),对照组采用体腔热灌注化疗,研究组采用贝伐珠单抗联合体腔热灌注化疗。对比两组的化疗效果,化疗前后的血清恶性生物学指标、原癌基因表达、不良反应发生情况及预后。结果研究组化疗后有效率与疾病控制率均高于对照组(P<0.05);化疗后两组的血清恶性肿瘤特异性生长因子(TSGF)、泌乳素(PRL)、血管内皮生长因子(VEGF)、糖类抗原125(CA125)水平均下降(P<0.05),研究组化疗后上述血清恶性生物学指标均低于对照组(P<0.05)。两组化疗后的原癌基因人类表皮生长因子受体2(c-erbB2)、髓细胞增生原癌基因(c-myc)、Kirsten大鼠肉瘤病毒癌基因同源物(K-ras)mRNA表达量均下降(P<0.05),研究组化疗后c-erbB2、c-myc、K-ras表达量均低于对照组(P<0.05)。两组的毒副反应发生率比较差异无统计学意义(P>0.05)。随访6~36个月,对照组与研究组的无进展生存率分别为47.70%、68.20%,无进展生存时间分别为10个月和16个月,总生存率分别为20.5%、42.20%,总生存时间分别为18个月和23个月,两组的无进展生存率(Log-Rankχ^(2)=7.404,P=0.007)和总生存率比较差异有统计学意义(Log-Rankχ^(2)=8.432,P=0.004)。结论对EC患者应用贝伐珠单抗联合体腔热灌注化疗的效果显著,能有效降低血清恶性生物学指标和原癌基因的水平,延长患者的生存时间,且安全性佳。Objective:To analyze the effect of bevacizumab combined with coelom hyperthermia perfusion on endometrial carcinoma(EC)and its influence on serum malignant biological indexes.Methods:89 EC patients,admitted between January 2018 and January 2020,were selected and divided into control group(44 patients)and study group(45 patients)by random number table method.The control group received coelom hyperthermia perfusion.The study group used bevacizumab combined with intraperitoneal thermoperfusion chemotherapy.The chemotherapy effect of the 2 groups was compared.Serum malignant biological indexes,proto-oncogene expression,occurrence of adverse reactions and prognosis before and after thechemotherapy.Results:Comparison of effective rate and disease control rate after chemotherapy was higher in the study group than in the control group(P<0.05).The serum levels of malignant tumour-specific growth factor(TSGF),prolactin(PRL),vascular endothelial growth factor(VEGF)and carbohydrate antigen 125(CA125)wasdecreased in both groups after the chemotherapy(P<0.05),and the above serum malignant biological indexes were lower in the study group than in the control group after the chemotherapy(P<0.05).The mRNA expression levels of proto-oncogene human epidermal growth factor receptor 2(c-erbB2),MYC oncogene(c-myc)and Kirsten ratsarcoma viral oncogene homolog(K-ras)wasdecreased after chemotherapy in both groups(P<0.05).The expression levels of c-erbB2,c-myc and K-ras in the study group after thechemotherapy were lower than those in the control group(P<0.05).There was no statistically significant difference in the incidence of toxic side effects between the 2 groups(P>0.05).During the follow-up period of 6 to 36 months,the pogression-free survival of control group and the study group were 47.70%and 68.20%,the median survival time of progression-free was 10 months and 16 months,the overall survival rate was 20.5%and 42.20%,and the median survival time of overall survival was 18 months and 23 months,respectively.The progression-free surviv

关 键 词：贝伐珠单抗 体腔热灌注化疗 子宫内膜癌 恶性肿瘤特异性生长因子 泌乳素 血管内皮生长因子 

分 类 号：R737.33[医药卫生—肿瘤]